Sonoma Bio is a biotechnology startup that operates in the healthcare sector, specifically in the field of autoimmune and inflammatory disease treatment. The company's primary focus is on developing living cell therapies that aim to restore balance to the immune system and potentially cure autoimmune diseases. This innovative approach utilizes the body's own immune response regulators to correct an overactive immune system, a common issue in autoimmune conditions.

Sonoma Bio's business model is centered around the research and development of these therapies. The company leverages the extensive research of its founders and a team of dedicated scientists to pioneer new treatments in Treg biology and cell therapy. The company's revenue is likely generated through partnerships with healthcare providers and institutions, as well as potential future sales of their developed therapies.

The company's target market includes patients suffering from autoimmune diseases and their care partners. Sonoma Bio is driven by a mission to not only find a cure for these diseases but also to significantly improve the quality of life for those affected by them.

The company's approach is rooted in scientific knowledge and collaboration, balancing these with a capable team that can execute their vision. They are committed to meeting the needs of patients and care partners, and their work is firmly grounded in science.

Keywords: Biotechnology, Healthcare, Autoimmune Diseases, Inflammatory Diseases, Living Cell Therapies, Immune System, Treg Biology, Cell Therapy, Scientific Research, Patient Care.